CelLBx Health

WALBROOK INVESTOR RELATIONS

CelLBxHealth plc (AIM: CLBX)

Company Summary

July 2026

Investment Profile

1. Global leader in the emerging CTC market - $0.5b market, projected to reach $1.0b by 2031
2. Commercially focused, partner-led and capital-efficient business model
3. Expect to achieve revenues of £8m+ in the medium term, with breakeven anticipated in 2028
4. Parsortix platform validated in 24 cancer types with 27 patents to 2034
5. Leadership team with strong commercial and clinical experience

Share Information

Ticker	AIM: CLBX
Share Price (GBX)	1.50
Shares in issue (b)	1.14
Market Cap (£m)	15.67
12m Hi/Low (GBX)	8.00/0.85

(Source: The London Stock Exchange, July 2026)

6-Month Share Price

(Source: The London Stock Exchange, July 2026)

Major Shareholders (as at June 2026)

Name	%
Conifer Management LLC	29.90
Dermot Keane	15.46
Global Frontier Investments, LLC	8.98

(Source: Company website)

Company Overview

CelLBxHealth plc (AIM: CLBX) is a CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology. Its patent-protected Parsortix® platform harvests CTCs from blood and can be integrated with existing lab instruments for comprehensive downstream analysis - including whole-cell imaging, proteomic profiling and full genomic workflows.

Commercial focus spans three revenue streams - Product Sales of the Parsortix platform and consumables through CRO and clinical lab partnerships, Lab Services including clinical trial support and assay development delivered from a GCLP-compliant UK facility, and Lab Developed Tests (LDTs), pursued through a combination of strategic partnerships and in-house development.

Significant and growing global market

1 in 2 diagnosed with cancer in their lifetime

19 million new cancer cases p.a., with 49 million people living with cancer (5-year prevalence)

65% growth in global cancer cases by 2050, with 31 million new cases p.a. by 2050

$25.2 trillion estimated global economic cost of cancer from 2020 to 2050, equivalent to an annual tax of 0.55% on global GDP

Cancer is a global issue which continues to grow every year. Current care fails to address patient needs, with tissue biopsies being the standard of care to confirm diagnosis. The biopsies are painful, costly and unsuitable for repeated use. CelLBxHealth's Parsortix platform addresses this unmet need, providing a repeatable, real-time cancer test to enable patients to get the right treatment at the right time. The CTC market is amounts to around $0.5b, and is projected to grow to $1.0b by 2031.

Parsortix: a proven platform

CTCs are increasingly recognised as critical to the development of targeted cancer therapies, such as ADCs, RLTs, and Cellular Therapies. Independent expert consensus confirms the clinical relevance of CTCs and identifies Parsortix as leading next-generation technology.

- Patented, scalable platform for capturing CTCs from blood
- Enables minimally invasive, cost-effective and repeatable testing of cancer cells
- Broad validation across 24 cancer types, accounting for >90% of solid tumours
- Cells compatible with standard protein, RNA, and DNA analysis
- Works with existing lab instruments, allowing for scalable integration
- 27 patents with coverage to 2034

WALBROOK INVESTOR RELATIONS
For more information email: CelLBx@walbrookpr.com
Tel: 020 7933 8780; web: www.walbrookpr.com

Business model: product and lab services focus

CelLBxHealth has implemented a strategic shift from science to commercialisation, driven by partnering with lab service providers and strategic partnerships, leveraging existing product sales. The Company is focused on three key pillars:

Product Sales - Accelerating Parsortix platform adoption and consumable sales through CROs and clinical lab partnerships

- Targeting contracts with four CROs and clinical labs
- Two technology transfer agreements to US clinical labs
- Successful bridging studies across multiple tissue-based tests

Lab Services - Clinical trial support and assay development

- Five pilot programmes anticipated
- Three assay development projects
- Two Phase I/II trials executed with pharma partners

Lab Developed Tests - Strategic partnerships using CTCs to expand the reach of existing tissue-based tests to generate recurring revenue

- Successful completion of NHS Lung Cancer study
- Launch of test development programme with Envita Medical Centers
- Launch of CelLBx Insight-Breast and GBM in 2028

All revenue streams leverage the same IP, improving ROI and scalability

Strategic partnerships driving product adoption

CelLBxHealth has a number of strategic partnerships applying CTCs to existing tissue and DNA-based tests, including a Master Services Agreement with AstraZeneca.

One significant partnership is with Myriad genetics, a leader in genetic testing with FDA-approved companion diagnostics. Under the current agreement, DNA from CTCs is being compared to patient tissue samples using Myriad's existing tissue-based assay. Following on from this, bridging studies undertaken by Myriad could result in the sale of Parsortix platforms and consumables.



FY25 highlights

- Total revenue of £1.4m (2024: £2.9m)
- Gross profit margins held at 62% (2024: 62%)
- Successful fundraise completed in December 2025 raising gross proceeds of £8.2m
- Cash of £4.3m at 31 March 2026
- Reduced annualised operating cash costs to approximately £6.7m
- Signed MSA with AstraZeneca for the use of Parsortix to potentially support drug discovery and development
- Strategic collaborations progressed with QIAGEN, Roche Diagnostics, Illumina and Myriad
- Board confident in delivering FY26 revenues of at least £2.1m (50% increase on FY25)

Key Newsflow

July: Result of AGM
July: AGM Statement
July: Directorate Change
June: Preliminary Results
May: MSA with Global Pharmaceutical Company
May: Collaboration with AdventHealth for two studies
May: Q1 trading update and outlook for 2026
April: Research Collab with The Royal Marsden
April: Board changes
Feb: Aligning Regulatory Approach with Commercial Needs

AGM statement from Exec Chair

Dr Jan Groen (Executive Chairman) has over 25 years of experience in clinical diagnostics and life science global markets. Jan has had board mandates in several life science companies, holds a PhD in Medical Microbiology from the Erasmus University Rotterdam, a BSc in Clinical Laboratory Studies and has published more than 125 papers in international scientific journals.

AGM statement (14.07.26)

"...the commercial opportunity for the Company remains significant. We continue to be focused on disciplined execution and converting our commercial pipeline into sustainable revenue growth and, importantly, we remain on track to deliver revenues for FY 2026 of at least £2.1 million, a 50% increase on FY 2025."

Meet CelLBxHealth

Watch the Company's most recent investor presentation by clicking below.



Forecasts (via Factset)

	2025A	2026E	2027E	2028E
Sales (£m)	1.4	2.1	5.6	8.3
Adj. EBITDA (£m)	(14.4)	(5.1)	(2.9)	0.1
Adj. EPS (p)	(5.7)	(0.46)	(0.28)	(0.06)